Gambro

In 2006, EQT and Investor AB together took the then listed Gambro, private through a public offer. The group was subsequently split into three independent companies: Diaverum, which operated the Gambro dialysis clinics was deemed non-core and was divested to Bridgepoint in 2007.

The blood component technologies unit, Caridian BCT, increased sales by more than 10 %. EBITDA was almost doubled during EQT’s ownership. R&D investments were significant and Caridian BCT strengthened its position in the important growth areas of Pathogen Reduction and Whole Blood Processing. In 2011, Caridian BCT was sold to listed Japanese medical technology company Terumo Corporation for a total enterprise value of USD 2,625 million. Caridian BCT is now the platform for Terumo’s blood technology operations.

The remaining part, Gambro, was the largest and oldest part of the original group and a leader in developing, manufacturing and supplying products and therapies for Kidney and Liver dialysis, Myeloma Kidney Therapy, and other extracorporeal therapies for Chronic and Acute patients. Gambro delivers solutions for In-center Care and Self Care haemodialysis, Renal Intensive Care and Hepatic Care. Dialysis saves the lives of a growing number of patients every year and the only current alternative to renal dialysis is kidney transplantation.

Gambro was sold to US listed medical technology group Baxter International Inc in 2013 for an enterprise value of SEK 26.5 billion.

Key events during EQT's ownership

  • Break-up of the Group and separation of the business completed in March 2007

  • Gambro Healthcare was divested in June 2007 to funds managed by Bridgepoint

  • Gambro renewed its product portfolio Gambro increased capacity: new fully automated dialyzer plant in the US and new blood line plant in the Czech Republic

  • Gambro undertook continuous cost reduction programs: restructuring of operations (started in 2007), SG&A reduction, a purchasing program and working capital improvement program

  • Divestment of CaridianBCT to Terumo Corporation was closed on 13 April 2011 at an Enterprise Value of USD 2 625 million

  • Dr. Guido Oelkers joined as President and CEO of Gambro in 2011

  • A capital injection was provided in June 2012 to support the first phase of the new Full Potential Plan. EQT IV’s portion amounted to EUR 40 million

  • On 4 December 2012, EQT IV and Investor AB signed an agreement with Baxter International Inc. to sell Gambro Group for an enterprise value of SEK 26.5 billion